R

Roche

Global pharmaceuticals and diagnostics company

Head of UK Pharma Finance Operations

Full-TimePosted on 10/20/2026Deadline 11/10/26
No salary listed
Expert
Welwyn, UK
In Person
AccountingAuditing, Financial Accounting

About the job

Requirements
  • A professional accounting qualification or equivalent senior finance-professional standing is required.
  • Significant senior-level experience in Finance, Accounting, Controllership, Financial Compliance, or Finance Operations within a complex organisation is required.
  • Demonstrated experience leading and developing experienced finance professionals and specialist individual contributors is required.
  • Strong technical grounding in financial accounting, financial controls, risk management, and corporate governance is required, with sound judgement on complex or ambiguous issues.
  • Experience across multiple finance disciplines and the ability to integrate accounting, controls, compliance, procurement, and business considerations into enterprise-level decisions are required.
  • The ability to operate effectively in a global matrix environment, including working with shared-service organisations and influencing stakeholders across local and global teams, is required.
  • The ability to influence senior leaders, constructively challenge decisions, and communicate complex financial or control issues clearly is required.
  • A track record of modernising finance processes and operating models through technology, automation, and emerging capabilities such as artificial intelligence is required, including identifying practical use cases and translating them into measurable workflow, productivity, and control-effectiveness improvements.
  • The ability to operate at strategic and detailed levels, set direction and lead through others, and personally engage in significant accounting, compliance, control, or operational matters when required is required.
Responsibilities
  • Act as Site Controller for Roche UK Pharma, maintaining oversight of significant financial matters across the site and providing a senior finance perspective on topics affecting the UK legal entity.
  • Lead the UK Finance Operations team, with direct leadership responsibility across Accounting, Internal Controls & Financial Compliance, and Procurement; set priorities, coach and develop the team, build succession, and ensure the required capabilities are available.
  • Act as a senior authorised Finance signatory for Roche UK Pharma, exercising delegated financial authority under Roche Group and local governance requirements; review and approve significant financial transactions, commitments, payments, and other matters requiring Finance authorisation, ensuring sound judgement, supporting evidence, segregation of duties, and appropriate escalation.
  • Own the overall financial compliance environment for Roche UK, translating Roche Group requirements and applicable UK statutory and regulatory obligations into effective local policies, processes, and controls.
  • Provide senior oversight of accounting and financial reporting, including complex accounting judgements, revenue recognition including VPAG and other contracted rebates, accruals, treasury, capital expenditure, payroll-related finance processes, pensions, and other material operational accounting topics.
  • Ensure the effectiveness of Roche UK's Internal Control over Financial Reporting environment, including risk assessment, control design, testing, remediation, and segregation of duties.
  • Own the local UK external audit process and act as the point of contact for external auditors; plan and execute the audit, resolve significant accounting and control matters, engage and escalate with UK and Group leadership, and coordinate with Roche Services & Solutions and other Roche teams.
  • Act as the senior local finance lead for financial compliance, internal audit, and assurance matters, proactively identifying risks and ensuring appropriate remediation and escalation.
  • Ensure Roche UK meets applicable transparency and Transfer of Value reporting requirements, including ABPI, Roche Group, and other local or global obligations.
  • Lead and oversee local site Procurement, ensuring value from third-party spend while maintaining appropriate sourcing, supplier-management, risk-management, and compliance standards.
  • Act as the key UK Finance Operations interface with Roche Services & Solutions, particularly the Chief Country Accountant and finance service teams, ensuring clear accountability, strong service delivery, and timely resolution of operational or control issues.
  • Build relationships with UK Tax, Group Finance, Group Financial Compliance, Procurement networks, and other global Finance organisations; represent UK requirements and ensure effective adoption of Roche standards and solutions.
  • Advise UK Finance and business leadership, connecting operational finance, control, and business insights and providing recommendations on complex or material financial matters.
  • Ensure foundational finance activities are delivered accurately and on time while simplifying processes, eliminating unnecessary activity, and making effective use of global capabilities, automation, and technology.
  • Lead the technology-enabled transformation of UK Finance Operations by identifying and implementing artificial intelligence, automation, and digital solutions in finance and procurement workflows; use technology to simplify processes, strengthen controls, improve decision-making, and increase productivity and functional impact within Group Technology infrastructure remits.
  • Maintain oversight of emerging financial, operational, and third-party risks and ensure significant matters are surfaced, understood, and addressed by appropriate senior stakeholders.
  • Foster ownership, sound judgement, and continuous improvement, enabling team members to work autonomously while maintaining financial stewardship, ethics, and compliance.
Desired Qualifications
  • Experience within Pharmaceuticals, Biotechnology, Healthcare, or another highly regulated industry.
  • Experience as a Controller, Finance Operations Head, Financial Compliance Officer, or in an equivalent senior fiduciary role.
  • Experience working with global finance shared-service or business-service organisations.
  • Experience spanning more than one of Accounting, Internal Controls/Audit, Procurement, Tax, or broader Finance Operations.

About the company

Roche is a global leader in pharmaceuticals and diagnostics. It develops medicines and diagnostic tools that help detect, monitor, and treat diseases, using research and biotechnology to drive new therapies and tests. Roche combines drug development with in-house diagnostic products to support personalized medicine, where treatments are tailored to individual patients based on test results. Its approach differs from many peers by integrating drug discovery with diagnostic capabilities and by expanding its research through strategic acquisitions (like Genentech) to strengthen its biotechnology and R&D capabilities. The company’s goal is to improve patient outcomes and healthcare worldwide by delivering reliable medicines, accurate diagnostic tests, and data-driven care.

Company Size

1-10

Company Stage

IPO

Headquarters

Basel, Switzerland

Founded

1896

Get referred to Roche

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Enicepatide delivered 15.5% weight loss in September 2026 and 22.7% in June.
  • pTau217 can scale immediately through Roche's existing lab network and improve Alzheimer diagnostics.
  • Roche's June 2026 data and September 2026 filings signal multiple obesity shots on goal.

What critics are saying

  • Eli Lilly and Novo Nordisk dominate obesity pricing, distribution, and physician mindshare today.
  • Enicepatide remains Phase II-only; Roche starts late-stage glycemic and cardiovascular studies in 2027.
  • If enicepatide disappoints, Roche burns its $2.7 billion Carmot bet and loses obesity credibility.

What makes Roche unique

  • Roche combines pharma, diagnostics, and installed cobas labs across 4,500 U.S. instruments.
  • Elecsys pTau217 won FDA clearance on August 24, 2026, and CE marking September 7.
  • Roche controls obesity assets from Carmot and Zealand, spanning GLP-1/GIP and amylin.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Performance Bonus

Company News

Yahoo Finance
Oct 22nd, 2026
Roche reaffirms outlook as Q3 sales rise 7% to $19.6B, but growth doubts linger

Roche reaffirmed its 2025 outlook on Thursday and beat third-quarter sales expectations, but questions about its long-term growth remain. Group sales rose 7% to 16.1 billion Swiss francs (about $19.6 billion), ahead of the 15.8 billion franc consensus estimate. Jefferies analyst Michael Leuchten said a new resource planning system boosted revenue, making the results "cosmetically ahead." Roche still expects group sales growth in the "mid single digit range" and did not raise guidance. Sales of allergy and asthma drug Xolair reached only 848 million francs, well below estimates. A copycat version launched in the US this month, and Ocrevus and Tecentriq face generic competition by 2030. Roche is counting on its breast cancer pill giredestrant, which awaits a US Food and Drug Administration decision by December 18, and on obesity drugs. It says the products could together reach $9 billion in peak annual sales.

CNBC
Oct 22nd, 2026
Roche CEO presses Germany on growth strategy as drugmaker pauses investment there

Roche chief executive officer Thomas Schinecker has challenged Germany over its growth strategy, saying pharmaceutical firms are "the industry they need to bet on." Schinecker discussed the company's third-quarter earnings and its recent expansion in China. He also outlined recent pharmaceutical developments at the business. He explained why Roche has paused investment in Germany.

Yahoo Finance
Oct 16th, 2026
FDA approves Roche's Enspryng as first at-home injection for thyroid eye disease

Roche said the US Food and Drug Administration (FDA) has approved Enspryng (satralizumab) for adults with thyroid eye disease (TED). It is the first and only at-home subcutaneous treatment for the condition, and a patient or caregiver can administer it after training. In the Phase III SatraGO-2 trial, 52.9% of active TED patients on Enspryng had a proptosis (eye bulging) response, against 23.4% on placebo. Double vision fell in 60.7% of patients, against 25.8%. The SatraGO-1 trial missed its primary endpoint at Week 24. No new safety signals emerged. TED affects about 155 in every 100,000 people in the US. This is Enspryng's second approval, after neuromyelitis optica spectrum disorder in 2020. The FDA is also reviewing it for myelin oligodendrocyte glycoprotein antibody-associated disease, with a decision expected in January 2027.

Yahoo Finance
Oct 9th, 2026
FDA approves Roche's Tecentriq for stage III colon cancer, cutting recurrence risk by 50%

The US Food and Drug Administration has approved Roche's Tecentriq in combination with a fluoropyrimidine and oxaliplatin for adjuvant treatment of stage III deficient DNA mismatch repair colon cancer. This marks Tecentriq's twelfth approved indication in the US. The approval follows the phase III ATOMIC study, published in The New England Journal of Medicine, which demonstrated that Tecentriq plus chemotherapy reduced the risk of disease recurrence or death by 50% compared to chemotherapy alone. The 36-month disease-free survival rate was 86% with the combination versus 76% with chemotherapy alone. Nearly 25% of colon cancers are diagnosed at stage III, and almost one in three stage III patients experience recurrence within five years. This represents the first approved adjuvant immunotherapy regimen for this patient population. Roche is pursuing further regulatory filings, including with the European Medicines Agency.

Yahoo Finance
Sep 30th, 2026
Roche's enicepatide shows 22.5% weight loss in 48 weeks, challenging Eli Lilly and Novo Nordisk

Roche posted strong Phase 2 results for its weight loss drug enicepatide, showing 22.5% mean weight loss over 48 weeks. This compares favourably to Eli Lilly's Zepbound, which achieved 20.2% weight loss over 72 weeks in a separate trial. In another Phase 2 study, enicepatide demonstrated HbA1c reductions of up to 2.65 percentage points in diabetic patients after 48 weeks, compared to tirzepatide's 2.37 percentage points after 52 weeks. Despite promising results, Roche faces stiff competition from Novo Nordisk and Eli Lilly, which both have deep pipelines in development. Novo Nordisk's CagriSema is nearing approval, whilst Eli Lilly's retatrutide has posted strong Phase 3 results. Roche's revenue grew 6% year over year in the first half of the year to 30.4 billion Swiss francs.